Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Natalie S. Callander et al.|New England Journal of Medicine|2023Cited by 695
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Adam D. Cohen et al.|Blood|2021Cited by 161
Deregulation of <i>FGFR1</i> and <i>CDK6</i> oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the <i>MIR9</i> familyPaula Rodríguez‐Otero, Felipe Prósper|British Journal of Haematology|2011Cited by 60
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myelomaBruno Paiva, Juan‐José Garcés, Gabriel Bretones et al.|Leukemia|2020Cited by 47